KLK3 and cancer: Oncolytic Ads with E1a controlled by cancer-selective promoters, such as OBP-301 (Telomelysin®) driven by human telomerase reverse transcriptase (hTERT) promoter [33] and CV706 driven by prostate-specific antigen (PSA) promoter [34], have progressed to human clinical trials.